Selective thyroid hormone receptor beta agonist, GC-1, is capable to reduce growth of colorectal tumor in syngeneic mouse models

References

• Schmohl KA, Han Y, Tutter M, et al. Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation. Endocr Relat Cancer. 2020;27(12):685–697.
   PubMed Web of Science ®Google Scholar
• Ciavardelli D, Bellomo M, Crescimanno C, et al. Type 3 deiodinase: role in cancer growth, stemness, and metabolism [mini review]. Front Endocrinol (Lausanne). 2014;5:215.
   PubMed Web of Science ®Google Scholar
• Nappi A, De Stefano MA, Dentice M, et al. Deiodinases and cancer. Endocrinology. 2021;162(4):bqab016.
   PubMed Web of Science ®Google Scholar
• López-Mateo I, Alonso-Merino E, Suarez-Cabrera C, et al. Thyroid hormone receptor β inhibits Self-Renewal capacity of breast cancer stem cells. Thyroid. 2020;30(1):116–132.
   PubMed Web of Science ®Google Scholar
• Martínez-Iglesias O, Garcia-Silva S, Tenbaum SP, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res. 2009;69(2):501–509.
   PubMed Web of Science ®Google Scholar
• Kim WG, Zhao L, Kim DW, et al. Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models. Thyroid. 2014;24(2):260–269.
   PubMed Web of Science ®Google Scholar
• Bolf EL, Gillis NE, Davidson CD, et al. Thyroid hormone receptor beta induces a Tumor-Suppressive program in anaplastic thyroid cancer. Mol Cancer Res. 2020;18(10):1443–1452.
   PubMed Web of Science ®Google Scholar
• Zhu L, Tian G, Yang Q, et al. Thyroid hormone receptor β1 suppresses proliferation and migration by inhibiting PI3K/Akt signaling in human colorectal cancer cells. Oncol Rep. 2016;36(3):1419–1426.
   PubMed Web of Science ®Google Scholar
• Guigon CJ, Kim DW, Zhu X, et al. Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology. 2010;151(11):5528–5536.
   PubMed Web of Science ®Google Scholar
• Porlan E, Vidaurre OG, Rodríguez-Peña A. Thyroid hormone receptor-beta (TR beta 1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2. Oncogene. 2008;27(19):2795–2800.
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.
   PubMed Web of Science ®Google Scholar
• Hörkkö TT, Tuppurainen K, George SM, et al. Thyroid hormone receptor β1 in normal Colon and colorectal cancer–association with differentiation, polypoid growth type and K‐ras mutations. Int J Cancer. 2006;118(7):1653–1659.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012–2024.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Webb P, Grover G, et al. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab. 2004;15(4):154–157.
   PubMed Web of Science ®Google Scholar
• Bleicher L, Aparicio R, Nunes FM, et al. Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct Biol. 2008;8(1):8.
   PubMedGoogle Scholar
• Terracina KP, Aoyagi T, Huang WC, et al. Development of a metastatic murine Colon cancer model. J Surg Res. 2015;199(1):106–114.
   PubMed Web of Science ®Google Scholar
• Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology. 2004;145(4):1656–1661.
   PubMed Web of Science ®Google Scholar
• Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, et al. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim (NY). 2013;42(6):217–224.
   PubMed Web of Science ®Google Scholar
• Cecchini MJ, Amiri M, Dick FA. Analysis of cell cycle position in mammalian cells. J Vis Exp. 2012;(59):3491. DOI:10.3791/3491
   PubMed Web of Science ®Google Scholar
• Castle JC, Loewer M, Boegel S, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 2014;15(1):190.
   PubMedGoogle Scholar
• Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl. 2005;26(3):422–428.
   PubMedGoogle Scholar
• Czarnecka AM, Matak D, Szymanski L, et al. Triiodothyronine regulates cell growth and survival in renal cell cancer. Int J Oncol. 2016;49(4):1666–1678.
   PubMed Web of Science ®Google Scholar
• Beber EH, Capelo LP, Fonseca TL, et al. The thyroid hormone receptor (TR) beta-selective agonist GC-1 inhibits proliferation but induces differentiation and TR beta mRNA expression in mouse and rat osteoblast-like cells. Calcif Tissue Int. 2009;84(4):324–333.
   PubMed Web of Science ®Google Scholar
• Chan IH, Privalsky ML. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene. 2006;25(25):3576–3588.
   PubMed Web of Science ®Google Scholar
• Kamiya Y, Puzianowska-Kuznicka M, McPhie P, et al. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis. 2002;23(1):25–33.
   PubMed Web of Science ®Google Scholar
• Kim WG, Cheng SY. Thyroid hormone receptors and cancer. Biochim Biophys Acta. 2013;1830(7):3928–3936.
   PubMed Web of Science ®Google Scholar
• Piqué DG, Greally JM, Mar JC. Identification of a novel subgroup of endometrial cancer patients with loss of thyroid hormone receptor beta expression and improved survival. BMC Cancer. 2020;20(1):857.
   PubMed Web of Science ®Google Scholar
• Gauthier BR, Sola-García A, Cáliz-Molina M, et al. Thyroid hormones in diabetes, cancer, and aging. Aging Cell. 2020;19(11):e13260.
   PubMed Web of Science ®Google Scholar
• Puliga E, Min Q, Tao J, et al. Thyroid hormone receptor-β agonist GC-1 inhibits Met-β-Catenin-Driven Hepatocellular Cancer. Am J Pathol. 2017;187(11):2473–2485.
   PubMed Web of Science ®Google Scholar
• Fanti M, Singh S, Ledda-Columbano GM, et al. Tri-iodothyronine induces hepatocyte proliferation by protein kinase A-dependent β-catenin activation in rodents. Hepatology. 2014;59(6):2309–2320.
   PubMed Web of Science ®Google Scholar
• Perra A, Kowalik MA, Pibiri M, et al. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology. 2009;49(4):1287–1296.
   PubMed Web of Science ®Google Scholar
• López‐Soto A, Huergo‐Zapico L, Acebes‐Huerta A, et al. NKG2D signaling in cancer immunosurveillance. Int J Cancer. 2015;136(8):1741–1750.
   PubMed Web of Science ®Google Scholar
• Dentice M, Luongo C, Ambrosio R, et al. β-Catenin regulates deiodinase levels and thyroid hormone signaling in Colon cancer cells. Gastroenterology. 2012;143(4):1037–1047.
   PubMed Web of Science ®Google Scholar